{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:47:52Z","timestamp":1788814072540,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,14]],"date-time":"2027-01-14T00:00:00Z","timestamp":1799884800000},"content-version":"am","delay-in-days":378,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.clml.2025.07.017","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T02:38:55Z","timestamp":1754447935000},"page":"19-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9702-8485","authenticated-orcid":false,"given":"Fadi G.","family":"Haddad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2634-4341","authenticated-orcid":false,"given":"Jennifer","family":"Croden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghayas C.","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2025.07.017_bib0001","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am J Hematol"},{"issue":"18","key":"10.1016\/j.clml.2025.07.017_bib0002","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia","volume":"333","author":"Jabbour","year":"2025","journal-title":"Jama"},{"key":"10.1016\/j.clml.2025.07.017_bib0003","unstructured":"American Cancer Society. Key Statistics for Chronic Myeloid Leukemia. 2025. https:\/\/www.cancer.org\/cancer\/types\/chronic-myeloid-leukemia\/about\/statistics.html. Accessed July 28, 2025."},{"issue":"5","key":"10.1016\/j.clml.2025.07.017_bib0004","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA: Can J Clin"},{"issue":"9593","key":"10.1016\/j.clml.2025.07.017_bib0005","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0140-6736(07)61510-4","article-title":"Chronic myeloid leukaemia in India","volume":"370","author":"Malhotra","year":"2007","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.clml.2025.07.017_bib0006","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2025.07.017_bib0007","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2013-08-283580","article-title":"How I treat leukemia during pregnancy","volume":"123","author":"Milojkovic","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.07.017_bib0008","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Therapeutic Advances in Hematology"},{"key":"10.1016\/j.clml.2025.07.017_bib0009","series-title":"Harrison's principles of internal medicine, 21e","article-title":"Chronic myeloid leukemia","author":"Kantarjian","year":"2022"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0010","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s12288-015-0519-0","article-title":"Obstetric complications and management in chronic myeloid leukemia","volume":"32","author":"Rohilla","year":"2015","journal-title":"Ind J Hematol Blood Transfus"},{"issue":"7","key":"10.1016\/j.clml.2025.07.017_bib0011","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1200\/JCO.2005.04.6557","article-title":"Pregnancy among patients with chronic myeloid leukemia treated with Imatinib","volume":"24","author":"Ault","year":"2006","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.017_bib0012","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2025.07.017_bib0013","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1002\/ajh.26550","article-title":"Treatment-free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors","volume":"97","author":"Haddad","year":"2022","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.clml.2025.07.017_bib0014","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.leukres.2008.09.012","article-title":"Persistence of molecular remission throughout pregnancy in CML after imatinib","volume":"33","author":"Sor\u00e0","year":"2009","journal-title":"Leukemia Res"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0015","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.3324\/haematol.10935","article-title":"Two successful pregnancies in a chronic myeloid leukemia patient treated with imatinib","volume":"92","author":"Garderet","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.clml.2025.07.017_bib0016","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.clml.2023.11.011","article-title":"SOHO State of the art updates and next questions: chronic myeloid leukemia and pregnancy: \u201cper Aspera ad Astra\u201d","volume":"24","author":"Abruzzese","year":"2024","journal-title":"Clin Lymphoma Myeloma and Leukemia"},{"issue":"4","key":"10.1016\/j.clml.2025.07.017_bib0017","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1182\/blood-2006-10-051391","article-title":"Imatinib concentrations in human milk","volume":"109","author":"Gambacorti-Passerini","year":"2007","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0018","article-title":"Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and review of literature","volume":"10","author":"Chelysheva","year":"2018","journal-title":"Mediterranean J Hematol Infect Dis"},{"issue":"12","key":"10.1016\/j.clml.2025.07.017_bib0019","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1093\/annonc\/mdi398","article-title":"Pregnancy outcome of two patients treated with imatinib","volume":"16","author":"Prabhash","year":"2005","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.clml.2025.07.017_bib0020","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3816\/CLM.2009.n.064","article-title":"Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature","volume":"9","author":"Cole","year":"2009","journal-title":"Clin Lymphoma and Myeloma"},{"issue":"12","key":"10.1016\/j.clml.2025.07.017_bib0021","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","article-title":"The effects of imatinib on pregnancy outcome","volume":"111","author":"Pye","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0022","first-page":"1","article-title":"Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978-2005","volume":"57","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.clml.2025.07.017_bib0023","doi-asserted-by":"crossref","first-page":"l869","DOI":"10.1136\/bmj.l869","article-title":"Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study","volume":"364","author":"Magnus","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clml.2025.07.017_bib0024","series-title":"Embryology, weeks 6-8","author":"Donovan","year":"2025"},{"issue":"3","key":"10.1016\/j.clml.2025.07.017_bib0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/10428194.2017.1347929","article-title":"Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment","volume":"59","author":"Chelysheva","year":"2017","journal-title":"Leukemia & Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0026","article-title":"Tyrosine kinase inhibitors and pregnancy","volume":"6","author":"Perrotti","year":"2014","journal-title":"Mediterranean J Hematol Infect Dis"},{"issue":"8","key":"10.1016\/j.clml.2025.07.017_bib0027","first-page":"997","article-title":"Recommandations du groupe Fi-LMC pour la gestion des effets ind\u00e9sirables du traitement par nilotinib (Tasigna\u00ae) au cours de la leuc\u00e9mie my\u00e9lo\u00efde chronique","volume":"97","author":"\u00c9tienne","year":"2010","journal-title":"Bulletin du Can"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0028","first-page":"22","article-title":"Loss of pregnancy in a patient with chronic myeloid leukemia during treatment with Nilotinib","volume":"6","author":"Arnall","year":"2016","journal-title":"J Hematol Oncol Pharm"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1756-8722-2-42","article-title":"Two successful pregnancies in a woman with chronic myeloid leukemia exposed to nilotinib during the first trimester of her second pregnancy: case study","volume":"2","author":"Conchon","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.07.017_bib0030","first-page":"74","article-title":"Delivery of two normal twins exposed to imatinib and nilotinib during the first trimester of pregnancy in a woman with chronic myeloid leukemia","volume":"2","author":"Mseddi","year":"2012","journal-title":"J Hematol Malig"},{"key":"10.1016\/j.clml.2025.07.017_bib0031","first-page":"1","article-title":"Pregnancy outcomes in chronic myeloid leukemia: a single center experience","volume":"5","author":"Madabhavi","year":"2019","journal-title":"J Glob Oncol"},{"issue":"Supplement_1","key":"10.1016\/j.clml.2025.07.017_bib0032","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/blood-2019-124430","article-title":"Pregnancy management in CML patients: to treat or not to treat? Report of 224 outcomes of the European leukemia Net (ELN) Database","volume":"134","author":"Chelysheva","year":"2019","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2025.07.017_bib0033","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1097\/CAD.0b013e328352a8fe","article-title":"A dramatic fetal outcome following transplacental transfer of dasatinib","volume":"23","author":"Berveiller","year":"2012","journal-title":"Anti-Can Drugs"},{"issue":"12","key":"10.1016\/j.clml.2025.07.017_bib0034","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1124\/dmd.108.022764","article-title":"Lacteal secretion, fetal and maternal tissue distribution of dasatinib in rats","volume":"36","author":"He","year":"2008","journal-title":"Drug Metabol Disposit"},{"issue":"12","key":"10.1016\/j.clml.2025.07.017_bib0035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.24186","article-title":"The impact of dasatinib on pregnancy outcomes","volume":"90","author":"Cortes","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0036","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.clp.2019.10.001","article-title":"Nonimmune Hydrops Fetalis","volume":"47","author":"Swearingen","year":"2020","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.clml.2025.07.017_bib0037","unstructured":"US FDA. Bosulif (bosutinib) prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/20334s007s008lbl.pdf. Accessed July 28, 2025."},{"issue":"2","key":"10.1016\/j.clml.2025.07.017_bib0038","doi-asserted-by":"crossref","first-page":"IJH2","DOI":"10.2217\/ijh-2020-0004","article-title":"Pregnancy outcomes in patients treated with bosutinib","volume":"9","author":"Cortes","year":"2020","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.07.017_bib0039","unstructured":"Ponatinib\u2019s investigator brochure. 2013."},{"key":"10.1016\/j.clml.2025.07.017_bib0040","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1016\/S2152-2650(21)01245-3","article-title":"Chronic myeloid leukemia and pregnancy: \u201cper Aspera ad Astra\u201d","volume":"21","author":"Abruzzese","year":"2021","journal-title":"Clin Lymphoma Myelom Leukem"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2025.07.017_bib0041","doi-asserted-by":"crossref","first-page":"2435-","DOI":"10.1182\/blood-2024-200186","article-title":"The impact of Ponatinib on pregnancy outcomes","volume":"144","author":"Abruzzese","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0042","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2013.03.001","article-title":"The developmental etiology and pathogenesis of Hirschsprung disease","volume":"162","author":"Butler Tjaden","year":"2013","journal-title":"Translation Res"},{"key":"10.1016\/j.clml.2025.07.017_bib0043","unstructured":"Asciminib\u2019s investigator brochure. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215358Orig1s000,Orig2s000MultidisciplineR.pdf. Accessed July 28, 2025."},{"key":"10.1016\/j.clml.2025.07.017_bib0044","unstructured":"Asciminib\u2019s investigator brochure. 2021. \u200bhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/215358s000Orig2lbl.pdf. Accessed July 28, 2025."},{"issue":"6","key":"10.1016\/j.clml.2025.07.017_bib0045","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1128\/AAC.37.6.1232","article-title":"Experimental study of transplacental passage of alpha interferon by two assay techniques","volume":"37","author":"Waysbort","year":"1993","journal-title":"Antimicrob Agents and Chemotherap"},{"issue":"11","key":"10.1016\/j.clml.2025.07.017_bib0046","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1111\/j.1471-0528.1986.tb08635.x","article-title":"Alpha interferon in human pregnancy","volume":"93","author":"Chard","year":"2005","journal-title":"BJOG: Int J Obstetr Gynaecol"},{"issue":"1","key":"10.1016\/j.clml.2025.07.017_bib0047","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<101::AID-AJH23>3.0.CO;2-D","article-title":"Interferon-alpha therapy for chronic myelogenous leukemia during pregnancy","volume":"59","author":"Kuroiwa","year":"1998","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2025.07.017_bib0048","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/ajh.20476","article-title":"Interferon-\u03b1 therapy for chronic myeloid leukemia during pregnancy","volume":"81","author":"Regierer","year":"2006","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.clml.2025.07.017_bib0049","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijgo.2003.11.014","article-title":"Pregnancy in chronic myeloid leukemia patients treated with alpha interferon","volume":"85","author":"Al Bahar","year":"2004","journal-title":"Int J Gynecol Obstetr"},{"issue":"2","key":"10.1016\/j.clml.2025.07.017_bib0050","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ajh.9876","article-title":"Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature","volume":"69","author":"Mubarak","year":"2002","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.clml.2025.07.017_bib0051","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1515\/JPM.2000.047","article-title":"Administration of interferon-\u03b1 during pregnancy: effects on fetus","volume":"28","author":"Hiratsuka","year":"2000","journal-title":"J Perinatal Med"},{"issue":"3","key":"10.1016\/j.clml.2025.07.017_bib0052","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/ajh.2830460312","article-title":"Familial myeloproliferative syndrome","volume":"46","author":"P\u00e9rez-Encinas","year":"2006","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2025.07.017_bib0053","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1038\/s41375-024-02183-0","article-title":"Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry","volume":"38","author":"Chelysheva","year":"2024","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.clml.2025.07.017_bib0054","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00403-020-02147-1","article-title":"Impact of congenital cutaneous hemangiomas on newborn care in the United States","volume":"313","author":"Tripathi","year":"2020","journal-title":"Arch Dermatolog Res"},{"issue":"4","key":"10.1016\/j.clml.2025.07.017_bib0055","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/cncr.11223","article-title":"Complete cytogenetic and molecular responses to interferon-\u03b1-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis","volume":"97","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"issue":"7_Part_1","key":"10.1016\/j.clml.2025.07.017_bib0056","first-page":"1448","article-title":"The effects of hydroxyurea and related compounds on the rat fetus","volume":"26","author":"Chaube","year":"1966","journal-title":"Can Res"},{"issue":"sup1","key":"10.1016\/j.clml.2025.07.017_bib0057","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3109\/10428199609074361","article-title":"Essential thrombocythemia and pregnancy","volume":"22","author":"Griesshammer","year":"1996","journal-title":"Leukemia & lymphoma"},{"issue":"8","key":"10.1016\/j.clml.2025.07.017_bib0058","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1038\/sj.leu.2402168","article-title":"Exposure to hydroxyurea during pregnancy: a case series","volume":"15","author":"Thauvin-Robinet","year":"2001","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2025.07.017_bib0059","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/ajh.26495","article-title":"Pregnancy outcomes with hydroxyurea use in women with sickle cell disease","volume":"97","author":"Kroner","year":"2022","journal-title":"Am J Hematol"},{"issue":"10","key":"10.1016\/j.clml.2025.07.017_bib0060","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/S0027-9684(15)31072-5","article-title":"Exposure to hydroxyurea and pregnancy outcomes in patients with sickle cell anemia","volume":"101","author":"Ballas","year":"2009","journal-title":"J Nation Med Associat"},{"issue":"4","key":"10.1016\/j.clml.2025.07.017_bib0061","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/10428194.2020.1849672","article-title":"Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-center experience","volume":"62","author":"Assi","year":"2020","journal-title":"Leukem Lymphom"},{"issue":"7","key":"10.1016\/j.clml.2025.07.017_bib0062","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2012-03-378919","article-title":"How I treat newly diagnosed chronic phase CML","volume":"120","author":"Cortes","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2025.07.017_bib0063","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","article-title":"Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Deininger","year":"2020","journal-title":"J Nation Comprehen Can Netw"},{"issue":"2","key":"10.1016\/j.clml.2025.07.017_bib0064","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s00404-016-4262-z","article-title":"Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers","volume":"295","author":"Carlier","year":"2016","journal-title":"Arch Gynecol Obstetr"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025002617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:53:29Z","timestamp":1768388009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025002617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2152265025002617"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.017","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Chronic Myeloid Leukemia During Pregnancy: Review of Evidence and Treatment Algorithm","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}